Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108


Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.

Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R.

PLoS One. 2013 Sep 6;8(9):e73817. doi: 10.1371/journal.pone.0073817. eCollection 2013. Erratum in: PLoS One.2014;9(8):e104307. doi: 10.1371/journal.pone.0104307.


Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM.

Clin Cancer Res. 2013 Oct 15;19(20):5777-87. doi: 10.1158/1078-0432.CCR-13-0351. Epub 2013 Aug 27.


Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.


Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD Jr, Ruan DT.

Surgery. 2011 Dec;150(6):1295-302. doi: 10.1016/j.surg.2011.09.014.


CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).

Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA.

J Biol Chem. 2011 May 20;286(20):17543-59. doi: 10.1074/jbc.M110.198515. Epub 2011 Mar 14.


Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.

Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD Jr, Clark OH, Ruan DT.

J Clin Endocrinol Metab. 2011 Mar;96(3):E554-65. doi: 10.1210/jc.2010-1800. Epub 2010 Dec 29.


Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer.

Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD Jr, Ruan DT.

Mol Cancer Res. 2010 Sep;8(9):1217-26. doi: 10.1158/1541-7786.MCR-10-0162. Epub 2010 Aug 24.


Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.

Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

J Surg Res. 2010 Sep;163(1):47-51. doi: 10.1016/j.jss.2010.04.018. Epub 2010 May 6.


The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.

Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2010 Feb 18;17(1):283-91. doi: 10.1677/ERC-09-0243. Print 2010 Mar.


Autophagy: a new target for advanced papillary thyroid cancer therapy.

Lin CI, Whang EE, Abramson MA, Jiang X, Price BD, Donner DB, Moore FD Jr, Ruan DT.

Surgery. 2009 Dec;146(6):1208-14. doi: 10.1016/j.surg.2009.09.019.


Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer.

Lin CI, Whang EE, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD Jr, Ruan DT.

Mol Cancer Res. 2009 Oct;7(10):1655-62. doi: 10.1158/1541-7786.MCR-09-0274. Epub 2009 Oct 13.


Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.

Satpathy M, Shao M, Emerson R, Donner DB, Matei D.

J Biol Chem. 2009 Jun 5;284(23):15390-9. doi: 10.1074/jbc.M808331200. Epub 2009 Mar 26.


Sall2 is a novel p75NTR-interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth.

Pincheira R, Baerwald M, Dunbar JD, Donner DB.

EMBO J. 2009 Feb 4;28(3):261-73. doi: 10.1038/emboj.2008.274. Epub 2009 Jan 8.


Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.

Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM, Moore FD Jr, Ruan DT.

Biochem Biophys Res Commun. 2009 Feb 6;379(2):626-31. doi: 10.1016/j.bbrc.2008.12.153. Epub 2009 Jan 3.


The Sall2 transcription factor is a novel p75NTR binding protein that promotes the development and function of neurons.

Pincheira R, Donner DB.

Ann N Y Acad Sci. 2008 Nov;1144:53-5. doi: 10.1196/annals.1418.026.


Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.

Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E.

Surgery. 2008 Dec;144(6):908-13; discussion 913-4. doi: 10.1016/j.surg.2008.07.028.


Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.

Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2009 Mar;16(1):267-79. doi: 10.1677/ERC-08-0127. Epub 2008 Nov 5.


Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD.

Cancer Res. 2007 Jan 15;67(2):450-4.


The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB.

J Biol Chem. 2007 Jan 5;282(1):445-53. Epub 2006 Nov 1.


Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.

Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD.

J Biol Chem. 2006 Jun 16;281(24):16814-20. Epub 2006 Apr 18.


Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52.

Gustin JA, Korgaonkar CK, Pincheira R, Li Q, Donner DB.

J Biol Chem. 2006 Jun 16;281(24):16473-81. Epub 2006 Apr 12.


p53 regulates Btk-dependent B cell proliferation but not differentiation.

Schmidt NW, Mayo LD, Donner DB, Kaplan MH.

J Leukoc Biol. 2006 Apr;79(4):852-9. Epub 2006 Feb 3.


Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.

Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB.

J Biol Chem. 2005 Jul 15;280(28):25953-9. Epub 2005 Apr 20.


Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells.

Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK, Donner DB.

Am J Physiol Cell Physiol. 2004 Mar;286(3):C547-55.


Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.

Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB.

J Biol Chem. 2004 Jan 16;279(3):1615-20. Epub 2003 Oct 29.


The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Mayo LD, Donner DB.

Trends Biochem Sci. 2002 Sep;27(9):462-7. Review.


Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.

Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, Welton ML.

Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1088-96.


PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.

Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB.

J Biol Chem. 2002 Feb 15;277(7):5484-9. Epub 2001 Nov 29.


A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Mayo LD, Donner DB.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603. Epub 2001 Aug 14.


The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity.

Gustin JA, Maehama T, Dixon JE, Donner DB.

J Biol Chem. 2001 Jul 20;276(29):27740-4. Epub 2001 May 16.


Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase.

Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB.

J Biol Chem. 2001 Jul 6;276(27):25184-9. Epub 2001 May 2.


A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5. Epub 2001 Apr 3.


Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt.

Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM.

J Biol Chem. 2001 Apr 27;276(17):13756-61. Epub 2001 Jan 30.


Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation.

Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB.

J Biol Chem. 2000 Apr 14;275(15):11216-21.


VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor.

Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB.

J Biol Chem. 2000 Mar 3;275(9):6059-62.


Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation.

Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB.

J Biol Chem. 2000 Feb 18;275(7):5096-103.


The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties.

Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, Toft DO.

J Biol Chem. 2000 Feb 4;275(5):3305-12.


NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase.

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB.

Nature. 1999 Sep 2;401(6748):82-5.


The proteasome regulates caspase-dependent and caspase-independent protease cascades during apoptosis of MO7e hematopoietic progenitor cells.

Wu LW, Reid S, Ritchie A, Broxmeyer HE, Donner DB.

Blood Cells Mol Dis. 1999 Feb;25(1):20-9.


Modulation of tumor necrosis factor and interleukin-1-dependent NF-kappaB activity by mPLK/IRAK.

Vig E, Green M, Liu Y, Donner DB, Mukaida N, Goebl MG, Harrington MA.

J Biol Chem. 1999 May 7;274(19):13077-84.


Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing.

Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, Warren RS, Friedman SL.

Oncogene. 1998 Jul 9;17(1):115-21.


Induction of Jak/STAT signaling by activation of the type 1 TNF receptor.

Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB.

J Immunol. 1998 Mar 15;160(6):2742-50.


Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma.

Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB.

J Biol Chem. 1996 Nov 15;271(46):29483-8.


Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine.

Marino MW, Dunbar JD, Wu LW, Ngaiza JR, Han HM, Guo D, Matsushita M, Nairn AC, Zhang Y, Kolesnick R, Jaffe EA, Donner DB.

J Biol Chem. 1996 Nov 8;271(45):28624-9.

Supplemental Content

Loading ...
Support Center